Study S000848

A Single Centre, Multiple Dose, Open Label Randomised Trial to Evaluate the Effect of Post Dose Meal Timings and the Effect of Volume of Water With Dosing on the Pharmacokinetic Properties of Oral Semaglutide in Healthy Male Subjects

ClinicalTrials.gov record

Registration

Registration: NCT01572753
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 161
Start: 2012-04-12
Primary completion: 2012-09-08
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:semaglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2010-019653-17; OTHER:U1111-1120-6776

Registered primary outcomes

AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing [0-24hrs after the 10th dosing]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011209	Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Overgaard RV, Clinical pharmacokinetics	2021	Other trial	PMID 33969456 DOI	cites ClinicalTrials.gov:NCT01572753; registry reference DERIVED:33969456
R0015802	Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation. Bækdal TA, Diabetes therapy : research, treatment and education of diabetes and related disorders	2021	Randomized trial	PMID 34080123 DOI	cites ClinicalTrials.gov:NCT01572753; registry reference DERIVED:34080123